Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy

A recently published review has discovered that considering genetic data for individuals who are suffering from drug-resistant focal epilepsy has led to the definition of novel illness entities and enhanced clinical decision making. Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, usually occurs when an individual has failed to stay free of seizures with sufficient trials of 2 ASMs (anti-seizure medication). The disease is often caused by brain lesions such as glioneural tumors.

These drugs must have been specifically chosen for the individual’s type of seizures and tried in combination with other seizure medications or on their own. Epilepsy surgery can be a curative treatment option for some patients.

Physicians usually identify these lesions using intracerebral electroencephalogram and magnetic resonance imaging (“MRIs”). However, these techniques lack the accuracy and specificity required to the lesions.

This led the research team to develop a tumor classifier that utilizes epigenetic profiling. The brain tumor classifier utilizes CpG sites in identifying different tumor groups and has shown to be useful in recognizing multiple tumor entities, including isomorphic diffuse glioma, glioneural tumors with nuclear clusters and primary mismatch repair-deficient IDH-mutant astrocytoma. These lesions, among many others, are difficult to diagnose without using molecular approaches and are usually morphologically heterogeneous.

In their report, the authors of the review discuss the different types of lesions that are linked to particular molecular markers. These lesions are brought about by a combination of germline and somatic variants, and they often impact glycosylation, receptor tyrosine kinase/mitogen-activate protein kinase (RTK/MPAK) signaling and mechanistic target of rapamycin (“mTOR”) signaling. These lesions can also be evaluated using cell-free DNA, without conducting a biopsy. This can be done using a cerebrospinal fluid sample that has been collected by a dural puncture.

However, the authors note in their report that this particular technique may require additional validation. Methylation profiles evaluated from peripheral blood can also be used to diagnose epilepsy, but studies on methylation in epilepsy are scarce at the moment. In addition, more studies and samples are required to assess the potential of DNA methylation in drug-resistant focal epilepsy.

The authors of the review conclude that molecular approaches are altering the diagnostic process for individuals suffering from this particular type of epilepsy. They note that the approaches could potentially be used by physicians to accurately give diagnoses of causal lesions based off of data collected using procedures that are less-invasive.

The neurology diagnosis segment is growing rapidly, and the improved diagnostic devices marketed by companies such as Brain Scientific Inc. (OTCQB: BRSF) are likely to enable earlier detection of conditions which compromise neurological health.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050